Aileron Therapeutics Inc
Buy, Hold or Sell?
Let's analyze Aileron Therapeutics Inc together
I guess you are interested in Aileron Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of Aileron Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
Get notifications about Aileron Therapeutics Inc
I send you an email if I find something interesting about Aileron Therapeutics Inc.
1. Quick Overview
1.1. Quick analysis of Aileron Therapeutics Inc (30 sec.)
1.2. What can you expect buying and holding a share of Aileron Therapeutics Inc? (30 sec.)
How much money do you get?
What is your share worth?
+ What do you gain per year?
2. Detailed Analysis
2.1. Valuation of Aileron Therapeutics Inc (5 min.)
2.2. Growth of Aileron Therapeutics Inc (5 min.)
Is Aileron Therapeutics Inc growing?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
How rich? | $101m | $17m | $35.5m | 67.5% |
How much money is Aileron Therapeutics Inc making?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
Making money | -$6.3m | -$4.2m | -$2m | -32.7% |
Net Profit Margin | -1,327.1% | 0.0% | - | - |
How much money comes from the company's main activities?
2.3. Financial Health of Aileron Therapeutics Inc (5 min.)
2.4. Comparing to competitors in the Biotechnology industry (5 min.)
Industry Rankings (Biotechnology)
3. Summary and Key Metrics
3.1. What can you expect buying and holding a share of Aileron Therapeutics Inc?
Welcome investor! Aileron Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Aileron Therapeutics Inc.
First you should know what it really means to hold a share of Aileron Therapeutics Inc. And how you can make/lose money.
Speculation
The Price per Share of Aileron Therapeutics Inc is $2.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.
If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:
- The fundamentals: the financial health trends of Aileron Therapeutics Inc.
- The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
- The book value: what is the market price compared to it's book value.
Investing
If you really want to invest in Aileron Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:
- You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.66. Based on the TTM, the Book Value Change Per Share is $1.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.18 per quarter.
- You may receive quarterly/yearly dividend in the form of additional shares.
- You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
How much money are you going to get?
MRQ | TTM | YOY | 5Y | 10Y | ||||||
---|---|---|---|---|---|---|---|---|---|---|
$ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | |
Usd Eps | -0.41 | -14.5% | -0.29 | -10.2% | -0.17 | -5.9% | -0.27 | -9.6% | -0.32 | -11.2% |
Usd Book Value Change Per Share | 0.45 | 15.7% | 1.02 | 35.7% | -0.18 | -6.4% | 0.16 | 5.8% | 0.13 | 4.7% |
Usd Dividend Per Share | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% |
Usd Total Gains Per Share | 0.45 | 15.7% | 1.02 | 35.7% | -0.18 | -6.4% | 0.16 | 5.8% | 0.13 | 4.7% |
Usd Price Per Share | 2.77 | - | 3.49 | - | 1.40 | - | 1.48 | - | 2.42 | - |
Price to Earnings Ratio | -1.68 | - | -3.37 | - | -3.05 | - | -1.74 | - | -2.16 | - |
Price-to-Total Gains Ratio | 6.20 | - | -7.01 | - | -11.44 | - | -8.51 | - | -8.28 | - |
Price to Book Ratio | 0.59 | - | 3.67 | - | 1.97 | - | 1.63 | - | 1.57 | - |
Price-to-Total Gains Ratio | 6.20 | - | -7.01 | - | -11.44 | - | -8.51 | - | -8.28 | - |
When do you get the money?
Usd Investment | |
---|---|
Usd Price Per Share | 2.85 |
Number of shares | 350 |
Gains per Quarter | Trailing 12 Months | 5 Year |
---|---|---|
Usd Dividend Per Share | 0.00 | 0.00 |
Usd Book Value Change Per Share | 1.02 | 0.16 |
Usd Total Gains Per Share | 1.02 | 0.16 |
Gains per Quarter (350 shares) | 356.32 | 57.38 |
Gains per Year (350 shares) | 1,425.26 | 229.51 |
Years | Return on Investment (TTM) | Return on Investment (5Y) | ||||
---|---|---|---|---|---|---|
Dividend | Book Value gain | Total gains | Dividend | Book Value gain | Total gains | |
Broker costs | - | - | -10 | - | - | -10 |
1 | 0 | 1425 | 1415 | 0 | 230 | 220 |
2 | 0 | 2851 | 2840 | 0 | 459 | 450 |
3 | 0 | 4276 | 4265 | 0 | 689 | 680 |
4 | 0 | 5701 | 5690 | 0 | 918 | 910 |
5 | 0 | 7126 | 7115 | 0 | 1148 | 1140 |
6 | 0 | 8552 | 8540 | 0 | 1377 | 1370 |
7 | 0 | 9977 | 9965 | 0 | 1607 | 1600 |
8 | 0 | 11402 | 11390 | 0 | 1836 | 1830 |
9 | 0 | 12827 | 12815 | 0 | 2066 | 2060 |
10 | 0 | 14253 | 14240 | 0 | 2295 | 2290 |
How sure are you?
Based on the past periods, how sure are you to get value out of your investment.
Linear %
Trailing 12 Months | 3Y | 5 Year | 10 Year | ALLTIME | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | % | % | % | % | ||||||||||||||||
Earnings Per Share | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 12.0 | 0.0 | 0.0% | 0.0 | 20.0 | 0.0 | 0.0% | 0.0 | 35.0 | 0.0 | 0.0% | 0.0 | 35.0 | 0.0 | 0.0% |
Book Value Change Per Share | 2.0 | 2.0 | 0.0 | 50.0% | 2.0 | 10.0 | 0.0 | 16.7% | 4.0 | 16.0 | 0.0 | 20.0% | 8.0 | 23.0 | 4.0 | 22.9% | 8.0 | 23.0 | 4.0 | 22.9% |
Dividend per Share | 0.0 | 0.0 | 4.0 | 0.0% | 0.0 | 0.0 | 12.0 | 0.0% | 0.0 | 0.0 | 20.0 | 0.0% | 0.0 | 0.0 | 35.0 | 0.0% | 0.0 | 0.0 | 35.0 | 0.0% |
Total Gains per Share | 2.0 | 2.0 | 0.0 | 50.0% | 2.0 | 10.0 | 0.0 | 16.7% | 4.0 | 16.0 | 0.0 | 20.0% | 8.0 | 23.0 | 4.0 | 22.9% | 8.0 | 23.0 | 4.0 | 22.9% |
3.2. Key Performance Indicators
The key performance indicators of Aileron Therapeutics Inc compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | 0.447 | 1.018 | -56% | -0.183 | +141% | 0.164 | +173% | 0.133 | +236% |
Book Value Per Share | - | - | 4.663 | 2.428 | +92% | 0.789 | +491% | 1.489 | +213% | 0.938 | +397% |
Current Ratio | - | - | 4.691 | 4.888 | -4% | 7.504 | -37% | 7.211 | -35% | 6.137 | -24% |
Debt To Asset Ratio | - | - | 0.077 | 0.304 | -75% | 0.143 | -47% | 0.232 | -67% | 0.671 | -89% |
Debt To Equity Ratio | - | - | 0.083 | 3.677 | -98% | 0.169 | -51% | 0.996 | -92% | 0.740 | -89% |
Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Eps | - | - | -0.413 | -0.291 | -29% | -0.167 | -59% | -0.273 | -34% | -0.320 | -23% |
Free Cash Flow Per Share | - | - | -0.387 | -0.296 | -23% | -0.221 | -43% | -0.268 | -31% | -0.275 | -29% |
Free Cash Flow To Equity Per Share | - | - | 0.456 | 0.278 | +64% | -0.221 | +149% | 0.012 | +3721% | 0.027 | +1583% |
Gross Profit Margin | - | - | 1.000 | 1.002 | 0% | 1.000 | +0% | 1.000 | +0% | 1.000 | +0% |
Intrinsic Value_10Y_max | - | - | -21.343 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | -18.117 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | -1.257 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -1.234 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | -4.448 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -4.233 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | -8.450 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -7.785 | - | - | - | - | - | - | - | - |
Market Cap | 61747530.000 | +3% | 60014266.000 | 75660223.470 | -21% | 30368410.215 | +98% | 32169054.853 | +87% | 52354291.459 | +15% |
Net Profit Margin | - | - | - | -13.271 | 0% | - | 0% | -2.654 | 0% | -1.517 | 0% |
Operating Margin | - | - | - | -13.552 | 0% | - | 0% | -2.710 | 0% | -1.549 | 0% |
Operating Ratio | - | - | - | 13.552 | -100% | - | 0% | 2.710 | -100% | 1.549 | -100% |
Pb Ratio | 0.611 | +3% | 0.594 | 3.675 | -84% | 1.967 | -70% | 1.628 | -64% | 1.571 | -62% |
Pe Ratio | -1.726 | -3% | -1.678 | -3.371 | +101% | -3.046 | +82% | -1.744 | +4% | -2.157 | +29% |
Price Per Share | 2.850 | +3% | 2.770 | 3.492 | -21% | 1.402 | +98% | 1.485 | +87% | 2.416 | +15% |
Price To Free Cash Flow Ratio | -1.840 | -3% | -1.788 | -3.803 | +113% | -1.906 | +7% | -1.640 | -8% | -2.541 | +42% |
Price To Total Gains Ratio | 6.374 | +3% | 6.195 | -7.015 | +213% | -11.440 | +285% | -8.510 | +237% | -8.279 | +234% |
Quick Ratio | - | - | 4.444 | 3.635 | +22% | 10.479 | -58% | 10.640 | -58% | 9.137 | -51% |
Return On Assets | - | - | -0.082 | -0.091 | +12% | -0.205 | +151% | -0.181 | +122% | -0.297 | +264% |
Return On Equity | - | - | -0.089 | -0.349 | +294% | -0.242 | +174% | -0.297 | +235% | -0.466 | +426% |
Total Gains Per Share | - | - | 0.447 | 1.018 | -56% | -0.183 | +141% | 0.164 | +173% | 0.133 | +236% |
Usd Book Value | - | - | 101021000.000 | 52610000.000 | +92% | 17096500.000 | +491% | 32251150.000 | +213% | 20317257.143 | +397% |
Usd Book Value Change Per Share | - | - | 0.447 | 1.018 | -56% | -0.183 | +141% | 0.164 | +173% | 0.133 | +236% |
Usd Book Value Per Share | - | - | 4.663 | 2.428 | +92% | 0.789 | +491% | 1.489 | +213% | 0.938 | +397% |
Usd Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Usd Eps | - | - | -0.413 | -0.291 | -29% | -0.167 | -59% | -0.273 | -34% | -0.320 | -23% |
Usd Free Cash Flow | - | - | -8389000.000 | -6422750.000 | -23% | -4789250.000 | -43% | -5801303.297 | -31% | -5947430.455 | -29% |
Usd Free Cash Flow Per Share | - | - | -0.387 | -0.296 | -23% | -0.221 | -43% | -0.268 | -31% | -0.275 | -29% |
Usd Free Cash Flow To Equity Per Share | - | - | 0.456 | 0.278 | +64% | -0.221 | +149% | 0.012 | +3721% | 0.027 | +1583% |
Usd Market Cap | 61747530.000 | +3% | 60014266.000 | 75660223.470 | -21% | 30368410.215 | +98% | 32169054.853 | +87% | 52354291.459 | +15% |
Usd Price Per Share | 2.850 | +3% | 2.770 | 3.492 | -21% | 1.402 | +98% | 1.485 | +87% | 2.416 | +15% |
Usd Profit | - | - | -8942000.000 | -6305250.000 | -29% | -4244750.000 | -53% | -6043550.000 | -32% | -6276714.286 | -30% |
Usd Revenue | - | - | - | 33500.000 | -100% | - | 0% | 6700.000 | -100% | 3828.571 | -100% |
Usd Total Gains Per Share | - | - | 0.447 | 1.018 | -56% | -0.183 | +141% | 0.164 | +173% | 0.133 | +236% |
EOD | +6 -2 | MRQ | TTM | +14 -18 | YOY | +19 -11 | 5Y | +21 -11 | 10Y | +20 -12 |
3.3 Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | -1.726 | |
Price to Book Ratio (EOD) | Between | 0-1 | 0.611 | |
Net Profit Margin (MRQ) | Greater than | 0 | 0.000 | |
Operating Margin (MRQ) | Greater than | 0 | 0.000 | |
Quick Ratio (MRQ) | Greater than | 1 | 4.444 | |
Current Ratio (MRQ) | Greater than | 1 | 4.691 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 0.077 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 0.083 | |
Return on Equity (MRQ) | Greater than | 0.15 | -0.089 | |
Return on Assets (MRQ) | Greater than | 0.05 | -0.082 | |
Total | 5/10 (50.0%) |
3.4 Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Rsi | Greater than | 50 | 43.341 | |
Ma 20 | Greater than | Ma 50 | 3.176 | |
Ma 50 | Greater than | Ma 100 | 3.445 | |
Ma 100 | Greater than | Ma 200 | 2.986 | |
Open | Greater than | Close | 2.880 | |
Total | 2/5 (40.0%) |
4. In-depth Analysis
4.1 About Aileron Therapeutics Inc
- https://www.aileronrx.com
- Biotechnology
- 15
- 12407 N. Mopac Expy., Austin, TX, United States, 78758
Google Maps Bing Maps
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
Fundamental data was last updated by Penke on 2024-11-14 09:45:04.
4.2 In-depth Summary
4.2.1. Financial Health Summary
Compared to previous year | Compared to industry | |
---|---|---|
The company is making a huge loss. | ||
Using its assets, the company is very inefficient in making profit. | ||
Using its investors money, the company is very inefficient in making profit. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is operating very inefficient. | ||
The company is inefficient in keeping operating costs low. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its short-term debts. | ||
The company is very able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its debts by selling its assets. | ||
The company is unable to pay all its debts with equity. |
4.2.2. Valuation Summary
Compared to previous year | Compared to industry | |
---|---|---|
Based on the equity, the company is fair priced. | ||
Based on the earnings, the company is expensive. | ||
Based on how much money comes from the company's main activities, the company is expensive. |
4.3 Financial Health
4.3.1. Profitability
4.3.1 Profitability
4.3.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
- A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of Aileron Therapeutics Inc:
- The MRQ is 0.0%. The data is not here.
Trends
- The 5Y is -265.4%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -151.7%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | - | TTM | -1,327.1% | +1,327.1% | |
TTM | -1,327.1% | YOY | - | -1,327.1% | |
TTM | -1,327.1% | 5Y | -265.4% | -1,061.6% | |
5Y | -265.4% | 10Y | -151.7% | -113.7% |
Compared to industry (Biotechnology)
Let compare the company's Net Profit Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -112.2%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -221.4%. trending down. -2
4.3.1.2. Return on Assets
- Above 5% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
- -8.2% Return on Assets means that Aileron Therapeutics Inc generated $-0.08 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of Aileron Therapeutics Inc:
Trends
- The YOY is -20.5%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is -18.1%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is -29.7%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -8.2% | TTM | -9.1% | +1.0% | |
TTM | -9.1% | YOY | -20.5% | +11.4% | |
TTM | -9.1% | 5Y | -18.1% | +9.0% | |
5Y | -18.1% | 10Y | -29.7% | +11.6% |
Compared to industry (Biotechnology)
Let compare the company's Return on Assets with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -11.3%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -11.7%. trending up. +2
4.3.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
- -8.9% Return on Equity means Aileron Therapeutics Inc generated $-0.09 for each $1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of Aileron Therapeutics Inc:
Trends
- The YOY is -24.2%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -29.7%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -46.6%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -8.9% | TTM | -34.9% | +26.0% | |
TTM | -34.9% | YOY | -24.2% | -10.6% | |
TTM | -34.9% | 5Y | -29.7% | -5.2% | |
5Y | -29.7% | 10Y | -46.6% | +16.9% |
Compared to industry (Biotechnology)
Let compare the company's Return on Equity with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -14.2%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -15.9%. trending down. -2
4.3.2. Operating Efficiency of Aileron Therapeutics Inc.
4.3.2. Operating Efficiency
4.3.2.1. Operating Margin
- Measures how much profit Aileron Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
- An Operating Margin of 0.0% means the company generated $0.00 for each $1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of Aileron Therapeutics Inc:
- The MRQ is 0.0%. The data is not here.
Trends
- The 5Y is -271.0%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -154.9%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | - | TTM | -1,355.2% | +1,355.2% | |
TTM | -1,355.2% | YOY | - | -1,355.2% | |
TTM | -1,355.2% | 5Y | -271.0% | -1,084.2% | |
5Y | -271.0% | 10Y | -154.9% | -116.2% |
Compared to industry (Biotechnology)
Let compare the company's Operating Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -222.9%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -310.7%. trending down. -2
4.3.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Biotechnology industry mean).
- An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.
Let's take a look of the Operating Ratio trends of Aileron Therapeutics Inc:
- The MRQ is 0.000. The data is not here.
Trends
- The 5Y is 2.710. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 1.549. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | - | TTM | 13.552 | -13.552 | |
TTM | 13.552 | YOY | - | +13.552 | |
TTM | 13.552 | 5Y | 2.710 | +10.842 | |
5Y | 2.710 | 10Y | 1.549 | +1.162 |
Compared to industry (Biotechnology)
Let compare the company's Operating Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.465. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 3.253. trending up. -2
4.4.3. Liquidity of Aileron Therapeutics Inc.
4.4.3. Liquidity
4.4.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
- A Current Ratio of 4.69 means the company has $4.69 in assets for each $1 in short-term debts.
Let's take a look of the Current Ratio trends of Aileron Therapeutics Inc:
Trends
- The YOY is 7.504. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 7.211. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 6.137. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 4.691 | TTM | 4.888 | -0.197 | |
TTM | 4.888 | YOY | 7.504 | -2.616 | |
TTM | 4.888 | 5Y | 7.211 | -2.323 | |
5Y | 7.211 | 10Y | 6.137 | +1.074 |
Compared to industry (Biotechnology)
Let compare the company's Current Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.637. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 3.890. trending up. +2
4.4.3.2. Quick Ratio
- Above 1 is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
- A Quick Ratio of 4.44 means the company can pay off $4.44 for each $1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of Aileron Therapeutics Inc:
Trends
- The YOY is 10.479. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 10.640. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 9.137. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 4.444 | TTM | 3.635 | +0.810 | |
TTM | 3.635 | YOY | 10.479 | -6.845 | |
TTM | 3.635 | 5Y | 10.640 | -7.005 | |
5Y | 10.640 | 10Y | 9.137 | +1.503 |
Compared to industry (Biotechnology)
Let compare the company's Quick Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.086. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 3.451. trending up. +2
4.5.4. Solvency of Aileron Therapeutics Inc.
4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare Aileron Therapeutics Inc to Biotechnology industry mean.
- A Debt to Asset Ratio of 0.08 means that Aileron Therapeutics Inc assets are financed with 7.7% credit (debt) and the remaining percentage (100% - 7.7%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of Aileron Therapeutics Inc:
Trends
- The YOY is 0.143. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.232. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.671. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.077 | TTM | 0.304 | -0.228 | |
TTM | 0.304 | YOY | 0.143 | +0.161 | |
TTM | 0.304 | 5Y | 0.232 | +0.072 | |
5Y | 0.232 | 10Y | 0.671 | -0.438 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.350. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.344. trending down. +2
4.5.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
- A Debt to Equity ratio of 8.3% means that company has $0.08 debt for each $1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of Aileron Therapeutics Inc:
Trends
- The YOY is 0.169. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.996. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.740. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.083 | TTM | 3.677 | -3.594 | |
TTM | 3.677 | YOY | 0.169 | +3.507 | |
TTM | 3.677 | 5Y | 0.996 | +2.680 | |
5Y | 0.996 | 10Y | 0.740 | +0.257 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.394. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.432. trending up. -2
4.6. Market Valuation
4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
- A PE ratio of -1.68 means the investor is paying $-1.68 for every $1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of Aileron Therapeutics Inc:
Trends
- The YOY is -3.046. Compared to the TTM, the mid term is trending down. +2
- The 5Y is -1.744. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is -2.157. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -1.726 | MRQ | -1.678 | -0.048 | |
MRQ | -1.678 | TTM | -3.371 | +1.693 | |
TTM | -3.371 | YOY | -3.046 | -0.325 | |
TTM | -3.371 | 5Y | -1.744 | -1.627 | |
5Y | -1.744 | 10Y | -2.157 | +0.413 |
Compared to industry (Biotechnology)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -2.403. trending up. -2
- The TTM average (mean) in the Biotechnology industry is -3.148. trending down. +2
4.6.2.2. Price To Free Cash Flow Ratio
Let's take a look of the Price To Free Cash Flow Ratio trends of Aileron Therapeutics Inc:
- The EOD is -1.840. Based on how much money comes from the company's main activities, the company is expensive. -2
- The MRQ is -1.788. Based on how much money comes from the company's main activities, the company is expensive. -2
- The TTM is -3.803. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
- The YOY is -1.906. Compared to the TTM, the mid term is trending down. +2
- The 5Y is -1.640. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is -2.541. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -1.840 | MRQ | -1.788 | -0.052 | |
MRQ | -1.788 | TTM | -3.803 | +2.014 | |
TTM | -3.803 | YOY | -1.906 | -1.897 | |
TTM | -3.803 | 5Y | -1.640 | -2.162 | |
5Y | -1.640 | 10Y | -2.541 | +0.901 |
Compared to industry (Biotechnology)
Let compare the company's priceToFreeCashFlowRatio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -3.234. trending up. -2
- The TTM average (mean) in the Biotechnology industry is -3.719. trending down. +2
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Biotechnology industry mean).
- A PB ratio of 0.59 means the investor is paying $0.59 for each $1 in book value.
Let's take a look of the Price to Book Ratio trends of Aileron Therapeutics Inc:
Trends
- The YOY is 1.967. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 1.628. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 1.571. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 0.611 | MRQ | 0.594 | +0.017 | |
MRQ | 0.594 | TTM | 3.675 | -3.080 | |
TTM | 3.675 | YOY | 1.967 | +1.708 | |
TTM | 3.675 | 5Y | 1.628 | +2.047 | |
5Y | 1.628 | 10Y | 1.571 | +0.057 |
Compared to industry (Biotechnology)
Let compare the company's Price to Book Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.051. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 2.356. trending up. -2
4.6.2. Total Gains per Share
4.7 Holders & Insider Transactions
Let's take a look at which institutions, funds and insiders are holding shares of Aileron Therapeutics Inc.
4.8.1. Institutions holding Aileron Therapeutics Inc
Institutions are holding 28.445% of the shares of Aileron Therapeutics Inc.
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2024-06-30 | University Of Texas Investment Mgmt Co | 8.2057 | 0.96 | 1777827 | 1777827 | 0 |
2024-06-30 | Nantahala Capital Management, LLC | 4.2866 | 0.0754 | 928734 | 673734 | 264.2094 |
2024-06-30 | Alyeska Investment Group, L.P. | 2.4924 | 0.0086 | 540000 | 540000 | 0 |
2024-06-30 | Vanguard Group Inc | 2.3362 | 0 | 506153 | 465839 | 1155.5266 |
2024-06-30 | Cable Car Capital LLC | 1.9385 | 1.2257 | 420000 | 420000 | 0 |
2024-06-30 | Prosight Management, LP | 1.2231 | 0.2194 | 265000 | 265000 | 0 |
2024-06-30 | RIMA MANAGEMENT, LLC | 1.0657 | 0.0221 | 230895 | 0 | 0 |
2024-06-30 | Geode Capital Management, LLC | 0.7867 | 0 | 170447 | 100688 | 144.3369 |
2024-06-30 | Sigma Planning Corp | 0.5826 | 0.0111 | 126225 | 58240 | 85.666 |
2024-06-30 | Kepos Capital LP | 0.4893 | 0.1142 | 106000 | 106000 | 0 |
2024-06-30 | Royal Bank of Canada | 0.278 | 0 | 60241 | 24241 | 67.3361 |
2024-06-30 | Gagnon Securities LLC | 0.1753 | 0.0237 | 37977 | 30 | 0.0791 |
2024-06-30 | Warberg Asset Management LLC | 0.1447 | 0.0131 | 31354 | 31354 | 0 |
2024-06-30 | BlackRock Inc | 0.1444 | 0 | 31285 | 31285 | 0 |
2024-06-30 | Blair William & Co | 0.1295 | 0.0002 | 28047 | -250 | -0.8835 |
2024-06-30 | Texas Capital Bank Wealth Management Services Inc | 0.1208 | 0.0075 | 26171 | 0 | 0 |
2024-06-30 | Northern Trust Corp | 0.1189 | 0 | 25763 | 25763 | 0 |
2024-06-30 | Renaissance Technologies Corp | 0.1148 | 0.0001 | 24864 | -20200 | -44.8251 |
2024-06-30 | State Street Corp | 0.048 | 0 | 10404 | 10404 | 0 |
2024-06-30 | Tower Research Capital LLC | 0.0178 | 0.0002 | 3864 | 1844 | 91.2871 |
Total | 24.699 | 2.6813 | 5351251 | +4511799 | +84.3% |
4.9.2. Funds holding Aileron Therapeutics Inc
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2024-09-30 | Vanguard Institutional Extnd Mkt Idx Tr | 1.9359 | 0.0014 | 419427 | -86363 | -17.0749 |
2024-09-30 | Fidelity Extended Market Index | 0.525 | 0.001 | 113743 | -2257 | -1.9457 |
2024-10-31 | iShares Micro-Cap ETF | 0.2117 | 0.021 | 45857 | 0 | 0 |
2024-09-30 | Fidelity Total Market Index | 0.1475 | 0.0001 | 31950 | 24275 | 316.2866 |
2024-09-30 | Fidelity Series Total Market Index | 0.1017 | 0.0001 | 22037 | 13870 | 169.8298 |
2024-09-30 | Northern Trust Extended Eq Market Idx | 0.0975 | 0.001 | 21130 | 0 | 0 |
2024-09-30 | NT Ext Equity Mkt Idx Fd - L | 0.0975 | 0.001 | 21130 | 0 | 0 |
2024-09-30 | Vanguard U.S. Eq Idx £ Acc | 0.059 | 0.0002 | 12774 | 12774 | 0 |
2024-09-30 | Fidelity Nasdaq Composite Index | 0.0442 | 0.0002 | 9579 | 0 | 0 |
2024-09-30 | Spartan Total Market Index Pool E | 0.0341 | 0.0001 | 7396 | 0 | 0 |
2024-10-31 | State St US Extended Mkt Indx NL Cl C | 0.0265 | 0.0012 | 5740 | 0 | 0 |
2024-09-30 | Spartan Extended Market Index Pool E | 0.0196 | 0.0004 | 4238 | 1277 | 43.1273 |
2024-09-30 | 1290 VT Micro Cap K | 0.0154 | 0.0073 | 3327 | 0 | 0 |
2024-09-30 | NT Ext Equity Mkt Idx Fd - NL | 0.0153 | 0.0002 | 3314 | 0 | 0 |
2024-09-30 | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 0.0151 | 0.001 | 3261 | 5 | 0.1536 |
2024-09-30 | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 0.0123 | 0.0002 | 2670 | 8 | 0.3005 |
2024-06-30 | SSgA U.S. Total Market Index Strategy | 0.0109 | 0.0001 | 2354 | 1939 | 467.2289 |
2024-09-30 | Northern Trust Wilshire 5000 | 0.0061 | 0.0002 | 1319 | 0 | 0 |
2024-10-31 | State St US Ttl Mkt Indx SL Cl I | 0.0018 | 0 | 400 | 0 | 0 |
2024-09-30 | Fidelity U.S. Equity Index Ins Trust | 0.0008 | 0.0001 | 175 | 0 | 0 |
Total | 3.3779 | 0.0368 | 731821 | -34472 | -4.7% |
5.3. Insider Transactions
Insiders are holding 0.65% of the shares of Aileron Therapeutics Inc.
5. Financial Statements
5.1. Latest Balance Sheet
Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 8,379 |
Total Stockholder Equity | + 101,021 |
Total Assets | = 109,400 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 2 |
Goodwill | 6,330 |
Intangible Assets | 79,200 |
Long-term Assets Other | 709 |
Long-term Assets (as reported) | 86,241 |
---|---|
Long-term Assets (calculated) | 86,241 |
+/- | 0 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Long-term Liabilities Other | 116 |
Long-term Liabilities (as reported) | 3,442 |
---|---|
Long-term Liabilities (calculated) | 116 |
+/- | 3,326 |
Total Stockholder Equity
Common Stock | 107 |
Retained Earnings | -304,572 |
Other Stockholders Equity | 360,503 |
Total Stockholder Equity (as reported) | 101,021 |
---|---|
Total Stockholder Equity (calculated) | 56,038 |
+/- | 44,983 |
5.2. Balance Sheets Structured
Currency in USD. All numbers in thousands.
Trend | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 109,400 | 99,192 | 106,008 | 12,822 | 13,991 | 17,157 | 22,007 | 27,232 | 33,770 | 40,255 | 48,481 | 54,768 | 60,531 | 64,671 | 16,341 | 22,239 | 26,125 | 20,373 | 26,473 | 33,952 | 40,193 | 22,399 | 30,312 | 38,133 | 42,577 | 52,688 | 52,688 | 59,036 | 15,105 | 17,155 | 22,021 | 0 | 0 | 0 | 5,940 | |||||||||||||||||||||||||||||||||||
> Total Current Assets |
| 23,159 | 12,764 | 18,266 | 12,793 | 13,952 | 17,105 | 21,873 | 27,054 | 33,550 | 39,993 | 48,177 | 54,423 | 60,152 | 64,324 | 16,326 | 15,974 | 19,670 | 13,687 | 19,550 | 26,497 | 32,559 | 14,389 | 21,775 | 30,053 | 37,206 | 51,840 | 51,840 | 58,117 | 11,992 | 15,982 | 21,073 | 0 | 0 | 0 | 4,026 | |||||||||||||||||||||||||||||||||||
Cash And Cash Equivalents |
| 21,942 | 12,067 | 17,313 | 12,069 | 13,167 | 7,783 | 5,194 | 4,839 | 7,628 | 7,449 | 3,600 | 7,603 | 10,748 | 19,283 | 7,046 | 7,850 | 17,124 | 10,697 | 5,311 | 6,867 | 10,157 | 11,272 | 10,635 | 7,716 | 11,980 | 11,863 | 11,863 | 13,428 | 9,397 | 8,029 | 20,715 | 0 | 0 | 0 | 3,768 | |||||||||||||||||||||||||||||||||||
Short-term Investments |
| 0 | 0 | 0 | 0 | 499 | 8,938 | 16,048 | 20,638 | 24,754 | 30,626 | 42,333 | 44,629 | 48,731 | 44,068 | 6,759 | 6,271 | 1,756 | 1,998 | 12,967 | 17,694 | 21,365 | 1,998 | 10,060 | 20,229 | 23,811 | 38,889 | 38,889 | 43,437 | 1,946 | 7,265 | 25 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Other Current Assets |
| 1,217 | 697 | 721 | 699 | 261 | 359 | 606 | 1,552 | 1,143 | 1,893 | 2,219 | 2,166 | 648 | 948 | 1,928 | 1,828 | 765 | 967 | 1,247 | 1,911 | 1,012 | 1,119 | 1,055 | 2,108 | 1,415 | 1,088 | 1,088 | 1,252 | 649 | 688 | 358 | 0 | 0 | 0 | 258 | |||||||||||||||||||||||||||||||||||
> Long-term Assets |
| 86,241 | 86,428 | 87,742 | 29 | 39 | 52 | 134 | 178 | 220 | 262 | 304 | 345 | 379 | 347 | 15 | 6,265 | 6,455 | 6,686 | 6,923 | 7,455 | 7,634 | 8,010 | 8,537 | 8,080 | 5,371 | 848 | 848 | 919 | 3,113 | 1,173 | 948 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Property Plant Equipment |
| 2 | 6 | 19 | 29 | 39 | 52 | 110 | 154 | 196 | 238 | 280 | 321 | 355 | 326 | 15 | 5,697 | 5,887 | 6,118 | 6,355 | 6,585 | 6,764 | 6,941 | 7,290 | 6,832 | 4,123 | 154 | 154 | 111 | 109 | 123 | 107 | 0 | 0 | 0 | 351 | |||||||||||||||||||||||||||||||||||
Goodwill |
| 6,330 | 6,330 | 6,330 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Intangible Assets |
| 79,200 | 79,200 | 79,200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Long-term Assets Other |
| 709 | 892 | 53 | 0 | 0 | 0 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 21 | 0 | 568 | 568 | 568 | 568 | 870 | 870 | 1,069 | 1,247 | 1,248 | 1,248 | 694 | 694 | 808 | 3,004 | 1,050 | 841 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
> Total Liabilities |
| 8,379 | 7,858 | 99,121 | 1,624 | 1,197 | 2,884 | 3,384 | 4,536 | 5,151 | 4,146 | 4,577 | 4,659 | 4,401 | 3,252 | 4,179 | 9,781 | 9,471 | 10,604 | 10,425 | 11,136 | 10,209 | 9,552 | 10,712 | 12,102 | 9,709 | 4,891 | 4,891 | 5,023 | 135,883 | 2,875 | 133,827 | 0 | 0 | 0 | 2,578 | |||||||||||||||||||||||||||||||||||
> Total Current Liabilities |
| 4,937 | 4,532 | 4,385 | 1,624 | 1,197 | 2,884 | 3,384 | 4,536 | 5,151 | 4,146 | 4,508 | 4,560 | 4,273 | 3,073 | 3,960 | 5,249 | 4,926 | 6,143 | 5,839 | 6,428 | 5,387 | 4,623 | 5,370 | 7,105 | 6,364 | 4,891 | 4,891 | 5,023 | 5,471 | 2,871 | 4,071 | 0 | 0 | 0 | 2,549 | |||||||||||||||||||||||||||||||||||
Short-term Debt |
| 0 | 48 | 0 | 0 | 0 | 0 | 33 | 67 | 100 | 131 | 93 | 93 | 93 | 422 | 168 | 560 | 661 | 468 | 446 | 426 | 406 | 387 | 0 | 0 | 1,020 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Short Long Term Debt |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 329 | 168 | 48 | 171 | 0 | 0 | 0 | 0 | 387 | 0 | 0 | 1,020 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Accounts payable |
| 782 | 2,156 | 1,190 | 484 | 136 | 458 | 1,720 | 945 | 1,741 | 1,023 | 1,210 | 1,035 | 1,016 | 560 | 1,596 | 1,002 | 993 | 1,088 | 1,452 | 2,349 | 1,719 | 858 | 1,731 | 2,994 | 1,583 | 1,600 | 4,891 | 1,650 | 2,212 | 1,035 | 1,971 | 0 | 0 | 0 | 641 | |||||||||||||||||||||||||||||||||||
Other Current Liabilities |
| 4,155 | 2,376 | 206 | 1,140 | 1,061 | 2,426 | 1,631 | 3,524 | 3,310 | 2,992 | 3,205 | 3,432 | 3,164 | 2,091 | 2,196 | 279 | 227 | 281 | 352 | 343 | 362 | 289 | 3,639 | 4,111 | 4,781 | 3,291 | 3,291 | 3,373 | 3,259 | 1,836 | 2,100 | 0 | 0 | 0 | 1,908 | |||||||||||||||||||||||||||||||||||
> Long-term Liabilities |
| 3,442 | 3,326 | 94,736 | 0 | 0 | 458 | 1,753 | 1,012 | 1,841 | 1,154 | 69 | 99 | 128 | 179 | 219 | 4,532 | 4,545 | 4,461 | 4,586 | 4,708 | 4,822 | 4,929 | 5,342 | 4,997 | 3,345 | 0 | 0 | 0 | 130,412 | 4 | 129,756 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Long term Debt Total |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5,342 | 4,997 | 3,345 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Capital Lease Obligations Min Short Term Debt |
| 0 | -48 | 48 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 69 | 99 | 128 | -205 | -168 | 4,148 | 4,161 | 4,461 | 4,586 | 4,708 | 4,822 | 4,929 | 0 | 0 | -1,020 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Warrants |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 130,412 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Other Liabilities |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,536 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5,342 | 4,997 | 3,345 | 0 | 0 | 0 | 0 | 4 | 11 | 0 | 0 | 0 | 29 | |||||||||||||||||||||||||||||||||||
> Total Stockholder Equity |
| 101,021 | 91,334 | 6,887 | 11,198 | 12,794 | 14,273 | 18,623 | 22,696 | 28,619 | 36,109 | 43,904 | 50,109 | 56,130 | 61,419 | 12,162 | 12,458 | 16,654 | 9,769 | 16,048 | 22,816 | 29,984 | 12,847 | 19,600 | 26,031 | 32,868 | 47,797 | 47,797 | 54,013 | -120,778 | 14,280 | -111,806 | 0 | 0 | 0 | 3,362 | |||||||||||||||||||||||||||||||||||
Common Stock |
| 107 | 103 | 0 | 91 | 91 | 91 | 91 | 91 | 91 | 91 | 91 | 91 | 90 | 90 | 44 | 40 | 39 | 28 | 28 | 28 | 28 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 0 | 11 | 0 | 0 | 0 | 0 | 4 | |||||||||||||||||||||||||||||||||||
Retained Earnings Total Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -268,238 | 0 | 0 | 0 | 0 | -231,953 | -226,267 | -219,292 | -214,296 | -209,273 | -204,883 | -198,135 | -190,900 | -183,151 | -175,979 | -168,493 | -161,459 | -154,025 | -144,534 | -136,946 | -130,081 | -123,822 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income |
| -22 | -63 | 0 | 0 | -2 | -10 | -48 | -98 | -101 | -75 | -13 | 1 | 6 | -7 | -2 | -1 | -2 | -1 | 7 | 17 | 24 | -1,206 | -5 | -3 | -12 | -33 | -1,979 | -6 | 0 | -2,116 | -2,094 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Capital Surplus |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 290,941 | 0 | 0 | 0 | 0 | 287,987 | 287,603 | 231,412 | 226,715 | 225,890 | 214,625 | 214,148 | 213,671 | 213,083 | 188,811 | 188,083 | 187,478 | 186,890 | 185,544 | 184,761 | 184,085 | 3,044 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||
Other Stockholders Equity |
| 360,503 | 340,340 | 0 | 292,285 | 292,056 | 291,756 | 291,365 | 290,941 | 290,499 | 289,971 | 289,282 | 288,674 | 287,987 | 287,603 | 231,412 | 226,715 | 225,890 | 214,625 | 214,148 | 213,671 | 213,083 | 188,811 | 188,083 | 187,478 | 186,890 | 184,761 | -33 | 125,049 | -127,368 | 135,284 | 4,630 | 0 | 0 | 0 | 0 |
5.3. Balance Sheets
Currency in USD. All numbers in thousands.
5.4. Cash Flows
Currency in USD. All numbers in thousands.
5.5. Income Statements
Currency in USD. All numbers in thousands.
5.6. Latest Income Statement
Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.
Gross Profit (+$) | ||
---|---|---|
totalRevenue | 0 | |
Cost of Revenue | -119 | |
Gross Profit | -119 | -119 |
Operating Income (+$) | ||
Gross Profit | -119 | |
Operating Expense | -16,276 | |
Operating Income | -16,276 | -16,395 |
Operating Expense (+$) | ||
Research Development | 3,991 | |
Selling General Administrative | 11,357 | |
Selling And Marketing Expenses | 119 | |
Operating Expense | 16,276 | 15,467 |
Net Interest Income (+$) | ||
Interest Income | 442 | |
Interest Expense | -0 | |
Other Finance Cost | -0 | |
Net Interest Income | 442 | |
Pretax Income (+$) | ||
Operating Income | -16,276 | |
Net Interest Income | 442 | |
Other Non-Operating Income Expenses | 0 | |
Income Before Tax (EBT) | -15,732 | -16,820 EBIT - interestExpense = -15,348 -14,804 -15,732 |
Interest Expense | 0 | |
Earnings Before Interest and Taxes (EBIT) | -15,348 | -15,732 |
Earnings Before Interest and Taxes (EBITDA) | -15,229 | |
After tax Income (+$) | ||
Income Before Tax | -15,732 | |
Tax Provision | -0 | |
Net Income From Continuing Ops | -12,940 | -15,732 |
Net Income | -15,732 | |
Net Income Applicable To Common Shares | 0 | |
Non-recurring Events | ||
Discontinued Operations | 0 | |
Extraordinary Items | 0 | |
Effect of Accounting Charges | 0 | |
Other Items | 0 | |
Non Recurring | 0 | |
Other Operating Expenses | 16,276 | |
Total Other Income/Expenses Net | 544 | -442 |
Technical Analysis of Aileron Therapeutics Inc
The psychology behind the price
Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.
General trend
First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aileron Therapeutics Inc. The general trend of Aileron Therapeutics Inc is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aileron Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.
Indicator phases
Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:
Indicator zone transitions | Bullish trend (-71.4%) | Bearish trend (71.4%) | |
---|---|---|---|
Overbought to neutral | Bullish pullback | = | Bearish reversal |
Upper to lower neutral | Bullish correction | = | Bearish continuation |
Nuetral to oversold | Oversold | = | Oversold |
Oversold to neutral | Bullish reversal | = | Bearish correction |
Lower to upper neutral | Bullish continuation | = | Bearish pullback |
Nuetral to overbought | Overbought | = | Overbought |
1. Price Targets
1.1 Support & Resistance
Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.
Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.
Score
Let's take a look at the Support & Resistance of Aileron Therapeutics Inc.
The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).
- Between support/resistance: The price is trading between support and resistance lines.
The bullish price targets are: 3.21 < 3.32 < 4.12.
The bearish price targets are: 2.33 > 1.61 > 1.12.
Tweet this2. Trend Indicators
2.1 Moving Averages
- Moving averages are lagging trend indicators.
- There are many types of moving averages.
- Moving averages are also used within other indicators.
Score
Let's take a look at the Moving Averages of Aileron Therapeutics Inc. The current mas is .
The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).
- MA 20 trending down: The MA 20 is trending down. -1
- Close < MA 20: The price is below the MA 20. -1
- MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
- MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
- MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
- MA 50 trending down: The MA 50 is trending down. -1
- Close < MA 50: The price is below the MA 50. -1
- MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
- MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
- MA 100 trending down: The MA 100 is trending down. -1
- Close < MA 100: The price is below the MA 100. -1
- MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
- MA 200 trending down: The MA 200 is trending down. -1
- Close < MA 200: The price is below the MA 200. -1
Directionalities and relatives.
Moving Average | Amount of candles | Trend | Price +/- | vs. MA 50 | vs. MA 100 | vs. MA 200 |
---|---|---|---|---|---|---|
MA 20 | 20 | |||||
MA 50 | 50 | - | ||||
MA 100 | 100 | - | - | |||
MA 200 | 200 | - | - | - |
Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I
2.2 Moving Average Convergence/Divergence (MACD)
- MACD is a lagging momentum indicator.
- Uses two moving averages.
- Can show buy or sell signals based on momentum.
- Can show overbought. and oversold. levels.
Score
Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aileron Therapeutics Inc. The current macd is -0.24400667.
The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).
- MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aileron Therapeutics Inc price going down in the near term. -2
- MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aileron Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aileron Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
- Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
2.3 Directional Movement Index (DMI)
The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.
Score
Let's take a look at the Directional Movement Index (DMI) of Aileron Therapeutics Inc. The current adx is 30.51.
The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).
- PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aileron Therapeutics Inc shares, leading to potential downward momentum in its price. -1
- PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
2.4 Parabolic SAR
- Parabolic SAR (stop and reverse) is a lagging trend indicator.
- Shows the current trend.
- Shows potential entry signals.
- Shows potential exit signals.
- Can be used to place trailing stoplosses..
Score
Let's take a look at the Parabolic SAR of Aileron Therapeutics Inc. The current sar is 2.341.
The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).
- Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
3. Momentum Indicators
3.1 Relative Strength Index (RSI)
- Leading momentum indicator, meaning the signals are instant.
- Ranges between 0 and 100.
- Above 70 is considered overbought.
- Below 30 is considered oversold.
- Above or below 50 can also be used to determine price trend or support and resistance.
- RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
- Can be used in many different ways
Score
Let's take a look at the Relative Strength Index (RSI) of Aileron Therapeutics Inc. The current rsi is 43.34. The current phase is Continuation in bear market.
The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).
- Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
- Trending up: The RSI is trending up. +1
3.2 Stochastic Oscillator
- Leading momentum indicator, meaning the signals are instant.
- Used to determine overbought and oversold areas much like the RSI.
- Ranges between 0 and 100.
- Above 80 is considered overbought.
- Below 20 is considered oversold.
- Consists of two lines named K and D.
- K compares the highest high and lowest low on the selected price range.
- The D line is a moving average of the K line.
- Can be used to spot divergences
Score
Let's take a look at the Stochastic Oscillator of Aileron Therapeutics Inc. The current phase is Continuation in bear market.
The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).
- STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
- STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aileron Therapeutics Inc price going up in the near term. +2
- Trending up: The STOCH %K is trending up. +1
3.3 Commodity Channel Index (CCI)
- Lagging or leading Momentum indicator
- When the CCI is above zero, the price is above the historical average
- When the CCI is below zero, the price is below the historical average
- Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend
Score
Let's take a look at the Commodity Channel Index (CCI) of Aileron Therapeutics Inc. The current cci is -43.1506958.
3.4 Chande Momentum Oscillator (CMO)
- Lagging momentum indicator
- Ranges between +100 and -100
- Considered overbought above +50
- Considered oversold below -50
- It's possible to add a moving average that acts as a signal line
Score
Let's take a look at the Chande Momentum Oscillator (CMO) of Aileron Therapeutics Inc. The current cmo is -8.20301129.
The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).
- CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
3.5 Williams %R
- Lagging momentum indicator
- Ranging between 0 and -100
- Above -20 is considered overbought
- Below -80 is considered oversold
- Is prone to give false signals
Score
Let's take a look at the Williams %R of Aileron Therapeutics Inc. The current willr is -63.40694006.
The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).
- WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Aileron Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.